Literature DB >> 24700069

Acute aortic dissection in a patient receiving multiple tyrosine kinase inhibitors for 5 years.

Y Funahashi1, N Sassa1, M Inada-Inoue2, Y Ando2, Y Matsukawa1, M Gotoh1.   

Abstract

A 48-year-old male presented with para-aortic lymph node metastases after surgical resection of a clear cell renal cell carcinoma. After first-line treatment with interferon alpha-2b, he was started on pazopanib and lapatinib. Blood pressure was well controlled with temocapril and amlodipine. Treatment had to be stopped 4 years and 8 months after initiation due to overt proteinuria. Then, sunitinib was started as third-line treatment. During the second cycle of sunitinib, he died due to a Stanford type A aortic dissection. Acute aortic dissection could be an adverse event associated with the long-term use of antiangiogenic tyrosine kinase inhibitors. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24700069     DOI: 10.1055/s-0033-1363274

Source DB:  PubMed          Journal:  Aktuelle Urol        ISSN: 0001-7868            Impact factor:   0.658


  3 in total

1.  Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System.

Authors:  Shuyue Wang; Mingzhu Chen; Xinghui Zhang; Lingjian Zhang; Min Jia; Zhiwen Shen; Junyan Wang; Bin Zhao; Yang Gong; Jian Gong
Journal:  J Am Heart Assoc       Date:  2021-11-30       Impact factor: 6.106

2.  A case of splenic artery aneurysm and rupture in a patient on a vascular endothelial growth factor inhibitor for renal cell carcinoma.

Authors:  Daniel Tesolin; Amer Alaref; Mohammed F K Ibrahim
Journal:  Cancer Rep (Hoboken)       Date:  2021-10-28

3.  Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma.

Authors:  Bailing Jiang; Junhe Li; Jun Chen; Xiaojun Xiang; Jianping Xiong; Jun Deng
Journal:  Thorac Cancer       Date:  2019-12-31       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.